Universal Beteiligungs und Servicegesellschaft mbH Trims Stake in United Therapeutics Corporation $UTHR

Key Points

• Universal Beteiligungs und Servicegesellschaft mbH trimmed its UTHR stake by 50.3% in Q4, selling 19,657 shares and leaving 19,418 shares valued at $9,483,000.
• Several analysts have raised price targets recently — the consensus is a “Moderate Buy” with an average price target of $601.50 (10 Buy ratings, 3 Hold ratings).
• Company insiders have been active sellers: the COO sold 22,500 shares and the CFO sold 10,000 shares, and insiders have sold 420,705 shares worth $226,250,141 over the last three months (insiders own 10.30%).

Universal Beteiligungs und Servicegesellschaft mbH reduced its holdings in shares of United Therapeutics Corporation (NASDAQ:UTHR - Free Report) by 50.3% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 19,418 shares of the biotechnology company's stock after selling 19,657 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH's holdings in United Therapeutics were worth $9,483,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in UTHR. WealthCollab LLC increased its stake in shares of United Therapeutics by 55.9% in the 2nd quarter. WealthCollab LLC now owns 106 shares of the biotechnology company's stock worth $30,000 after purchasing an additional 38 shares in the last quarter. Rakuten Securities Inc. raised its holdings in United Therapeutics by 76.7% in the 2nd quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company's stock worth $30,000 after purchasing an additional 46 shares during the period. Wilmington Savings Fund Society FSB lifted its position in United Therapeutics by 125.6% during the third quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company's stock valued at $37,000 after purchasing an additional 49 shares in the last quarter. Abich Financial Wealth Management LLC bought a new stake in United Therapeutics during the third quarter valued at about $44,000. Finally, Geneos Wealth Management Inc. grew its holdings in United Therapeutics by 141.7% during the first quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company's stock valued at $45,000 after purchasing an additional 85 shares during the period. 94.08% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

UTHR has been the topic of several recent research reports. UBS Group raised their price objective on United Therapeutics from $655.00 to $705.00 and gave the stock a "buy" rating in a research note on Thursday, March 5th. Morgan Stanley boosted their price target on shares of United Therapeutics from $471.00 to $519.00 and gave the stock an "equal weight" rating in a research note on Friday, April 10th. Royal Bank Of Canada raised their target price on shares of United Therapeutics from $587.00 to $643.00 and gave the company an "outperform" rating in a report on Thursday, February 26th. Cantor Fitzgerald raised their price objective on United Therapeutics from $525.00 to $625.00 and gave the company an "overweight" rating in a research note on Thursday, March 12th. Finally, Bank of America lifted their price target on shares of United Therapeutics from $569.00 to $626.00 and gave the stock a "neutral" rating in a research note on Tuesday, March 31st. Ten investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat.com, United Therapeutics currently has an average rating of "Moderate Buy" and an average price target of $601.50.

Insider Buying and Selling at United Therapeutics

In other news, COO Michael Benkowitz sold 22,500 shares of the stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $470.95, for a total value of $10,596,375.00. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, CFO James Edgemond sold 10,000 shares of United Therapeutics stock in a transaction dated Monday, March 23rd. The stock was sold at an average price of $527.48, for a total value of $5,274,800.00. Following the sale, the chief financial officer directly owned 18,876 shares of the company's stock, valued at $9,956,712.48. This trade represents a 34.63% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 420,705 shares of company stock worth $226,250,141. 10.30% of the stock is owned by insiders.

United Therapeutics Price Performance

Shares of UTHR stock opened at $567.16 on Monday. United Therapeutics Corporation has a 1-year low of $272.12 and a 1-year high of $607.89. The company has a market cap of $24.86 billion, a price-to-earnings ratio of 20.33, a price-to-earnings-growth ratio of 1.61 and a beta of 0.75. The stock's fifty day moving average price is $536.51 and its 200 day moving average price is $494.61.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last released its earnings results on Wednesday, February 25th. The biotechnology company reported $7.70 EPS for the quarter, topping analysts' consensus estimates of $6.78 by $0.92. United Therapeutics had a net margin of 41.94% and a return on equity of 19.30%. The company had revenue of $790.20 million during the quarter, compared to analysts' expectations of $814.80 million. During the same period last year, the business earned $6.19 EPS. United Therapeutics's revenue for the quarter was up 7.4% on a year-over-year basis. As a group, equities research analysts anticipate that United Therapeutics Corporation will post 27.97 earnings per share for the current year.

United Therapeutics Profile

United Therapeutics Corporation NASDAQ: UTHR is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company's primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.

Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Corporation (NASDAQ:UTHR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.